SecBot SecBot
SECBOTREPLAY Home › Report › AZN

AZN · AstraZeneca's Datroway (datopotamab deruxtecan) received EU approval as…

ASTRAZENECA PLC · 6-K filed Jul 31, 2026 at 06:54 ET

At the news

BULLISHIMPACT 7/10

6-K filed Jul 31, 2026 at 06:54 ET

AstraZeneca's Datroway (datopotamab deruxtecan) received EU approval as monotherapy for 1st-line metastatic triple-negative breast cancer (TNBC) in patients ineligible for immunotherapy, based on the TROPION-Breast02 Phase III trial showing a 5.0-month median overall survival improvement (23.7 vs 18.7 months, HR 0.79) and a 43% reduction in progression/death risk. This expands Datroway's EU label to two breast cancer indications and positions it as the only TROP2-directed ADC with an overall survival benefit in this setting, reinforcing AstraZeneca's oncology growth trajectory.

  • EU approval for 1st-line metastatic TNBC in patients not candidates for PD-1/PD-L1 inhibitor therapy.
  • Approval based on TROPION-Breast02 Phase III trial: median OS 23.7 months (Datroway) vs 18.7 months (chemotherapy); HR 0.79 (p=0.0291).
  • Risk of disease progression or death reduced by 43% (HR 0.57; p<0.0001); ORR 62.5% vs 29.3%.
  • Datroway now approved for two breast cancer indications in the EU (HR+/HER2- and TNBC).

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access